{"id":48852,"date":"2022-09-27T13:02:20","date_gmt":"2022-09-27T11:02:20","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/"},"modified":"2022-09-27T13:02:20","modified_gmt":"2022-09-27T11:02:20","slug":"silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/","title":{"rendered":"Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference"},"content":{"rendered":"
\n

LONDON–(BUSINESS WIRE)–$SLN<\/a> #SenseofSilence<\/a>–Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Giles Campion, MD, Head of R&D and Chief Medical Officer, will participate in a fireside chat at the Chardan Genetic Medicines Conference on Tuesday, October 4th<\/sup> at 3:45 p.m. ET in New York.\n<\/p>\n

<\/a><\/p>\n

\nA live webcast of the fireside chat will be available on the Investors section of the Silence website at www.silence-therapeutics.com<\/a>.\n<\/p>\n

\nAbout Silence Therapeutics
\n
<\/b>Silence Therapeutics is developing a new generation of medicines by harnessing the body\u2019s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence\u2019s proprietary mRNAi GOLD\u2122 platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence\u2019s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https:\/\/www.silence-therapeutics.com\/<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nEnquiries:<\/b>
Silence Therapeutics plc<\/b>
Gem Hopkins, Head of IR and Corporate Communications
\n
ir@silence-therapeutics.com<\/a>
Tel: +1 (646) 637-3208\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON–(BUSINESS WIRE)–$SLN #SenseofSilence–Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Giles Campion, MD, Head of R&D and Chief Medical Officer, will participate in a fireside … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48852","6":"format-standard","7":"category-industry"},"yoast_head":"\nSilence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON–(BUSINESS WIRE)–$SLN #SenseofSilence–Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Giles Campion, MD, Head of R&D and Chief Medical Officer, will participate in a fireside ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-27T11:02:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220927005131\/en\/1582575\/21\/Silence-Logo-FINAL-rgb.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference\",\"datePublished\":\"2022-09-27T11:02:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\\\/\"},\"wordCount\":271,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220927005131\\\/en\\\/1582575\\\/21\\\/Silence-Logo-FINAL-rgb.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\\\/\",\"name\":\"Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220927005131\\\/en\\\/1582575\\\/21\\\/Silence-Logo-FINAL-rgb.jpg\",\"datePublished\":\"2022-09-27T11:02:20+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220927005131\\\/en\\\/1582575\\\/21\\\/Silence-Logo-FINAL-rgb.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220927005131\\\/en\\\/1582575\\\/21\\\/Silence-Logo-FINAL-rgb.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/","og_locale":"en_US","og_type":"article","og_title":"Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference - Pharma Trend","og_description":"LONDON–(BUSINESS WIRE)–$SLN #SenseofSilence–Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Giles Campion, MD, Head of R&D and Chief Medical Officer, will participate in a fireside ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-27T11:02:20+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220927005131\/en\/1582575\/21\/Silence-Logo-FINAL-rgb.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference","datePublished":"2022-09-27T11:02:20+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/"},"wordCount":271,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220927005131\/en\/1582575\/21\/Silence-Logo-FINAL-rgb.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/","url":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/","name":"Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220927005131\/en\/1582575\/21\/Silence-Logo-FINAL-rgb.jpg","datePublished":"2022-09-27T11:02:20+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220927005131\/en\/1582575\/21\/Silence-Logo-FINAL-rgb.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220927005131\/en\/1582575\/21\/Silence-Logo-FINAL-rgb.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-participate-in-fireside-chat-at-chardan-genetic-medicines-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48852","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48852"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48852\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48852"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48852"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48852"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}